SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001520138-20-000531
Filing Date
2020-11-05
Accepted
2020-11-05 17:09:01
Documents
44
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bivi-20200930_10q.htm 10-Q 293868
2 EX-31.1 bivi-20200930_10qex31z1.htm EX-31.1 12104
3 EX-31.2 bivi-20200930_10qex31z2.htm EX-31.2 12220
4 EX-32.1 bivi-20200930_10qex32z1.htm EX-32.1 5288
5 EX-32.2 bivi-20200930_10qex32z2.htm EX-32.2 5131
  Complete submission text file 0001520138-20-000531.txt   1928721

Data Files

Seq Description Document Type Size
6 XBRL PRESENTATION FILE bivi-20200930_pre.xml EX-101.PRE 138259
7 XBRL INSTANCE FILE bivi-20200930.xml EX-101.INS 326184
8 XBRL SCHEMA FILE bivi-20200930.xsd EX-101.SCH 24729
9 XBRL CALCULATION FILE bivi-20200930_cal.xml EX-101.CAL 29126
10 XBRL DEFINITION FILE bivi-20200930_def.xml EX-101.DEF 70753
11 XBRL LABEL FILE bivi-20200930_lab.xml EX-101.LAB 186153
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

IRS No.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39015 | Film No.: 201291493
SIC: 2834 Pharmaceutical Preparations